natgillin/translations-raw huggingface dataset:
De hyppigste bivirkninger af en hvilken som helst grad (oplevet af mindst 20 % af patienterne) omfatter diaré, PPES, vægttab, nedsat appetit, kvalme, træthed, dysgeusi, ændringer i hårfarve, hypertension, stomatitis, konstipation, opkastning, slimhindeinflammation, asteni og dysphoni. 
The most frequent adverse reactions of any grade (experienced by at least 20% of patients) included diarrhoea, PPES, weight decreased, decreased appetite, nausea, fatigue, dysgeusia, hair colour changes, hypertension, stomatitis, constipation, vomiting, mucosal inflammation, asthenia, and dysphonia.
Når dosisreduktion er nødvendig, anbefales det at reducere til 100 mg daglig, administreret som én 80 mg orange kapsel og én 20 mg grå kapsel, og derefter til 60 mg daglig, administreret som tre 20 mg grå kapsler. 
When dose reduction is necessary, it is recommended to reduce to 100 mg daily, taken as one 80 mg orange capsule and one 20 mg grey capsule, and then to 60 mg daily, taken as three 20 mg grey capsules.
én orange 80 mg + én grå 20 mg 
one orange 80 mg + one grey 20 mg
Du må ikke tage COMETRIQ sammen med mad. 
You should not take COMETRIQ with food.
Derfor bør co-administration af potente CYP3A4-hæmmere (f.eks. ritonavir, itraconazol, erythromycin, clarithromycin, grapefrugtjuice) med cabozantinib foretages med forsigtighed. 
Therefore co-administration of strong CYP3A4 inhibitors (e.g., ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice) with cabozantinib should be approached with caution.
Meget almindelige bivirkninger (kan påvirke flere end 1 ud af 10 mennesker) 
Very common side effects (may affect more than 1 in 10 people)
• Generaliserede smerter, bryst- eller muskelsmerter, ørepine, ringen for ørerne 
• Generalised pain, chest or muscle pain, ear pain, ringing in ears
Cabozantinib var en hæmmer (IC50 = 7,0 μM), men ikke et substrat, af P-glykoprotein (P-gp) transportaktiviteter i et to-rettet assay-system, der anvender MDCK-MDR1 celler. 
Cabozantinib was an inhibitor (IC50 = 7.0 μM), but not a substrate, of P-glycoprotein (P-gp) transport activities in a bi-directional assay system using MDCK-MDR1 cells.
Resultater fra et studie med patienter med nedsat leverfunktion indikerer, at eksponeringen (AUC0-inf) øgedes med henholdsvis 81 % og 63 % hos forsøgspersoner med let og moderat nedsat leverfunktion (90 % CI for AUC0-inf: 121,44 % til 270,34 % ved let og 107,37 % til 246,67 % ved moderat nedsat leverfunktion). 
Results from a study in patients with hepatic impairment indicate that exposure (AUC0-inf) increased by 81% and 63% in subjects with mild and moderate hepatic impairment, respectively (90% CI for AUC0-inf: 121.44% to 270.34% for mild and 107.37% to 246.67% for moderate).
De hårde kapsler er grå med “XL184 20mg” trykt i sort på kapslens krop. 
The hard capsules are grey with “XL184 20mg” printed in black on the body of the capsule.
• Smerter i munden, tænderne og/eller kæben, hævelse eller sår inde i munden, manglende følelse i eller en følelse af tyngde i kæben eller løsnen af en tand. 
• Pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth.
- Gem indlægsedlen. 
- Keep this leaflet.
(XL184-N-oxid og XL184 amid spaltningsprodukt), der besidder <1 % af on-target kinasehæmningspotentialet af moderstoffet cabozantinib, hver repræsenterende <10 % af total lægemiddelrelateret plasmaeksponering. 
Two non-conjugated metabolites (XL184-N-oxide and XL184 amide cleavage product), which possess <1% of the on-target kinase inhibition potency of parent cabozantinib, each represent <10% of total drug-related plasma exposure.
tre grå 20 mg 
three grey 20 mg
Patienter med svært nedsat nyrefunktion er ikke blevet undersøgt. 
Patients with severe hepatic impairment have not been studied.
Midler til modificering af gastrisk pH 
Gastric pH modifying agents
De mest almindelige alvorlige bivirkninger forbundet med cabozantinib er pneumoni, slimhinde inflammation, hypokalcæmi, dysfagi, dehydrering, lungeemboli og hypertension. 
The most common serious adverse reactions associated with cabozantinib are pneumonia, mucosal inflammation, hypocalcaemia, dysphagia, dehydration, pulmonary embolism, and hypertension.
Der kræves forsigtighed ved administration af cabozantinib med midler, der er stærke CYP3A4-hæmmere. 
Caution is required when administering cabozantinib with agents that are strong CYP3A4 inhibitors.
• Træthed, svaghed, hovedpine, svimmelhed 
• Fatigue, weakness, headache, dizziness
De hårde kapsler er orange med ”XL184 80mg” trykt i sort på kapslens krop. 
The hard capsules are orange with “XL184 80mg” printed in black on the body of the capsule.
Resultater fra et studie hos patienter med nedsat nyrefunktion indikerer, at ratioerne af middelværdierne beregnet ved mindste kvadraters metode for plasme-cabozantinib, Cmax og AUC0-inf var 19 % og 30 % højere hos forsøgspersoner med let nedsat nyrefunktion (90 % CI for Cmax 91,60 % til 155,51 %; AUC0-inf 98,79 % til 171,26 %) og 2 % og 6-7 % højere (90 % CI for Cmax 78,64 % til 133,52 %; AUC0-inf 79,61 % til 140,11 %) hos forsøgspersoner med moderat nedsat nyrefunktion sammenlignet med forsøgspersoner med normal nyrefunktion. 
Results from a study in patients with renal impairment indicate that the ratios of geometric LS mean for plasma cabozantinib, Cmax and AUC0-inf were 19% and 30% higher, for subjects with mild renal impairment (90% CI for Cmax 91.60% to 155.51%; AUC0-inf 98.79% to 171.26%) and 2% and 6-7% higher (90% CI for Cmax 78.64% to 133.52%; AUC0-inf 79.61% to 140.11%), for subjects with moderate renal impairment compared to subjects with normal renal function.
Kapslens indhold Mikrokrystallinsk cellulose Croscarmellosenatrium Natriumstivelsesglycolat Kolloid vandfri silica Stearinsyre 
Capsule content Microcrystalline cellulose Croscarmellose sodium Sodium starch glycolate Silica colloidal anhydrous Stearic acid
Indlægsseddel er inden i posen. 
Package leaflet inside pouch.
• Symptomer omfattende smerter i maven, kvalme, opkastning, forstoppelse eller feber. 
• Symptoms including pain in the abdomen, nausea, vomiting, constipation, or fever.
• 140 mg (1 orange 80 mg kapsel og 3 grå 20 mg kapsler) 
• 140 mg (1 orange 80 mg capsule and 3 grey 20 mg capsules)
har for højt blodtryk har eller har haft et aneurisme (udvidelse og svækkelse af en blodårevæg) eller en rift i en blodårevæg har diaré har en nylig baggrund med at hoste blod op eller væsentlig blødning har gennemgået operation inden for den sidste måned (eller hvis et kirurgisk indgreb er planlagt), inklusive dentale indgreb har fået strålebehandling inden for de sidste 3 måneder har inflammatorisk tarmsygdom (for eksempel Crohn's sygdom eller ulcerativ colitis eller diverticulitis) har fået at vide, at din cancer har spredt sig til dine luftveje eller spiserøret har en nylig baggrund med blodprop i benet, hjerneblødning eller hjerteanfald tager lægemidler for at kontrollere din hjerterytme, har en langsom hjertefrekvens, har problemer med dit hjerte eller har problemer med niveauerne af calcium, kalium eller magnesium i dit blod har svær lever- eller nyresygdom. 
- have had surgery within the last month (or if surgical procedures are planned), including dental procedures - have had radiotherapy in the last 3 months - have inflammatory bowel disease (for example, Crohn's disease or ulcerative colitis or diverticulitis) - have been told that your cancer has spread to your airway or oesophagus - have a recent history of blood clot in the leg, stroke, or heart attack - are taking medicines to control your heart rhythm, have a slow heart rate, have problems with your heart or have problems with the levels of calcium, potassium or magnesium in your blood - have severe liver or kidney disease.
Bivirkninger, der generelt opstår tidligt, omfatter hypokalcæmi, hypokaliæmi, thrombocytopeni, hypertension, palmoplantar erythrodysæsthesi-syndrom (PPES), og gastrointestinale (GI) bivirkninger (abdominal- og mundsmerter, slimhindeinflammation, konstipation, diaré, opkastning. 
Events that generally have early onset include hypocalcaemia, hypokalaemia, thrombocytopenia, hypertension, palmarplantar erythrodysaesthesia syndrome (PPES), and gastrointestinal (GI) events (abdominal or mouth pain, mucosal inflammation, constipation, diarrhoea, vomiting).
• Blister, smerter i hænderne eller fodsålerne, udslæt på eller rødmen af huden, tør hud 
• Blister, pain of the hands or soles of the feet, rash or redness of the skin, dry skin
Hos rotter medførte cabozantinib postimplantationstab, føtalt ødem, hareskår/ganespalte, dermal aplasi og knækket eller rudimentær hale. 
In rats, cabozantinib caused postimplantation loss, foetal oedema, cleft palate/lip, dermal aplasia and kinked or rudimentary tail.
Administration af den potente CYP3A4-hæmmer ketoconazol (400 mg daglig i 27 dage) til raske frivillige sænkede cabozantinib clearance (med 29 %) og øgede enkeltdosis plasma cabozantinib eksponering (AUC) med 38 %. 
Administration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 27 days) to healthy volunteers decreased cabozantinib clearance (by 29%) and increased single-dose plasma cabozantinib exposure (AUC) by 38%.
• Ansigtsmerter 
• Haemorrhoids
• Rift eller hul eller blødning i din mave eller tarmene, inflammation eller rift i endetarmsåbningen, blødninger i lungerne eller luftrøret 
• Tear or hole or bleeding in your stomach or intestine, inflammation or tear of anus, , bleeding in lungs or trachea (airway)
Den anbefalede dosis COMETRIQ er 140 mg én gang daglig, taget som én 80 mg orange kapsel og tre 20 mg grå kapsler. 
The recommended dose of COMETRIQ is 140 mg once daily, taken as one 80 mg orange capsule and three 20 mg grey capsules.
• Hævelse, smerter i dine hænder og fødder, eller kortåndethed. 
• Swelling, pain in your hands and feet, or shortness of breath.
Administration af MRP2-hæmmere kan resultere i øget cabozantinib-plasmakoncentration. 
Administration of MRP2 inhibitors may result in increases in cabozantinib plasma concentrations.
Det skal du vide, før du begynder at tage COMETRIQ 
What you need to know before you take COMETRIQ
Yderligere oplysninger om dette lægemiddel findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu hjemmeside og på Lægemiddelstyrelsens hjemmeside www.dkma.dk. 
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Samtidig administration af cabozantinib med den stærke CYP3A4-inducer rifampicin resulterede i et fald i cabozantinib plasmaeksponering. 
Concurrent administration of cabozantinib with the strong CYP3A4 inducer rifampicin resulted in a decrease in cabozantinib plasma exposure.
Sort jernoxid (E172) Propylenglycol 
Black iron oxide (E172) Propylene glycol
• 100 mg (1 orange 80 mg kapsel og 1 grå 20 mg kapsel) 
• 100 mg (1 orange 80 mg capsule and 1 grey 20 mg capsule)
Samtidige administreret lægemidler der er potente hæmmere af CYP3A4, bør anvendes med forsigtighed, og kronisk administration af lægemidler, der er potente induktorer af CYP3A4, bør undgås (se pkt. 
Concomitant medicinal products that are strong inhibitors of CYP3A4 should be used with caution, and chronic use of concomitant medicinal products that are strong inducers of CYP3A4 should be avoided (see sections 4.4 and 4.5).
EVENTUELLE ANDRE SÆRLIGE ADVARSLER Dispenseringsinstruktioner 
OTHER SPECIAL WARNING(S), IF NECESSARY Dispensing instructions
Administration af MRP2-hæmmere kan derfor resultere i øget cabozantinib-plasmakoncentration. 
Therefore, administration of MRP2 inhibitors may result in increases in cabozantinib plasma concentrations.
Palmoplantar erytrodysæstesi-syndrom (PPES) er blevet observeret med cabozantinib. 
Palmar-plantar erythrodysaesthesia syndrome (PPES) has been observed with cabozantinib.
Bivirkninger i form af venøs thromboemboli og arteriel thromboemboli er blevet observeret med cabozantinib. 
Events of venous thromboembolism and events of arterial thromboembolism have been observed with cabozantinib.
Kronisk co-administration af potente CYP3A4inducere (f.eks. phenytoin, carbamazepin, rifampicin, phenobarbital eller naturlægemidler indeholdende perikon [Hypericum perforatum]) med cabozantinib bør derfor undgås. 
Chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing St. John's Wort [Hypericum perforatum]) with cabozantinib should therefore be avoided.
Cabozantinib anbefales ikke til patienter med svært nedsat leverfunktion, da sikkerheden og virkningen ikke er blevet fastslået hos denne population. 
Cabozantinib is not recommended for use in patients with severe renal impairment as safety and efficacy have not been established in this population.
Almindelige bivirkninger (kan påvirke op til 1 ud af 10 mennesker) 
Common side effects (may affect up to 1 in 10 people)
Brug af anden medicin sammen med COMETRIQ 
Other medicines and COMETRIQ
- Kapsel indhold: mikrokrystallinsk cellulose, croscarmellosenatrium, natriumstivelsesglycolat, kolloid vandfri silica og stearinsyre. 
- Capsule contents: microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, silica colloidal anhydrous, and stearic acid
Samtidig administration af cabozantinib med den stærke CYP3A4-hæmmer ketoconazol resulterede i en øgning i cabozantinib plasmaeksponering. 
Concurrent administration of cabozantinib with the strong CYP3A4 inhibitor ketoconazole resulted in an increase in cabozantinib plasma exposure.
• Inflammation af læberne eller mundvigene 
• Inflammation of the lips and corners of the mouth
Sort jernoxid (E172) Titandioxid (E171) 
Titanium dioxide (E171)
Yderligere oplysninger om dette lægemiddel findes på Det Europæiske Lægemiddelagenturs http://www.ema.europa.eu hjemmeside og på Lægemiddelstyrelsens hjemmeside www.dkma.dk. 
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
5.2), kan plasmaprotein fortrænges, som en mulig interaktion med warfarin. 
Because of high plasma protein binding levels of cabozantinib (section 5.2) a plasma protein displacement interaction with warfarin may be possible.
Administration af den potente CYP3A4-inducer rifampicin (600 mg daglig i 31 dage) til raske frivillige øgede cabozantinib-clearance (4,3 gange) og reducerede eksponeringen af cabozantinib i plasma (AUC) efter en enkelt dosis med 77 %. 
Administration of the strong CYP3A4 inducer rifampicin (600 mg daily for 31 days) to healthy volunteers increased cabozantinib clearance (4.3-fold) and decreased single-dose plasma cabozantinib exposure (AUC) by 77%.
• Uro i maven, inklusive diaré, kvalme, opkastning, forstoppelse, fordøjelsesbesvær og mavesmerter 
• Stomach upset, including diarrhoea, nausea, vomiting, constipation, indigestion, and abdominal pain
Undersøgelser vægttab, ALAT, ASAT og alkalisk fosfatase i serum forhøjet, blod-LDH forhøjet, blod-TSH forhøjet, lymfopeni, neutropeni, trombocytopeni blodkreatinkinase forhøjet aktiveret partiel tromboplastintid forkortet, eosinofiltælling forhøjet, trombocyttælling forhøjet 
Investigations weight decreased, serum ALT, AST, and ALP increased, blood LDH increased, blood TSH increased, lymphopenia, neutropenia, thrombocytopenia blood creatinine phosphokinase increased activated partial thromboplastin time shortened, eosinophil count increased, platelet count increased
Vaskulære sygdomme hypertension hypotension, venøs trombose, bleghed, perifer kølighed arteriel trombose Aneurismer og arterielle dissektioner 
Vascular disorders hypertension hypotension, venous thrombosis, pallor, peripheral coldness arterial thrombosis Aneurysms and artery dissections
Cabozantinib skal seponeres hos patienter, der oplever ONJ. 
Cabozantinib should be discontinued in patients who experience ONJ.
CYP3A4-hæmmere og -inducere 
CYP3A4 inhibitors and inducers
Nervesystemet dysgeusi, hovedpine, svimmelhed cerebrovaskulær hændelse, perifer neuropati, paræstesi, ageusi, tremor ataksi, opmærksomhedsforstyrrelse, hepatisk encefalopati, bevidsthedstab, talebesvær, posterior reversibelt encefalopatisyndr om 
Nervous system disorders dysgeusia, headache, dizziness cerebrovascular accident, peripheral neuropathy, paraesthesia, ageusia, tremor ataxia, disturbance in attention, hepatic encephalopathy, loss of consciousness, speech disorder, posterior reversible encephalopathy syndrome
Hud og subkutane væv palmoplantar erytrodysæstesisyndrom, ændringer i hårfarve, udslæt, tør hud, alopeci, erytem hyperkeratose, akne, blister, unormal hårvækst, hudafskalning, hypopigmentation af huden hudsår, telangiectasi 
Skin and subcutaneous tissue disorders palmar-plantar erythrodysaesthesia syndrome, hair colour changes, rash, dry skin, alopecia, erythema hyperkeratosis, acne, blister, hair growth abnormal, skin exfolation, skin hypopigmentation skin ulcer, telangiectasia
• Rødmen, hævelse eller smerter i munden eller svælget, taleproblemer, hæshed 
• Redness, swelling or pain in the mouth or throat, difficulty in speaking, hoarseness
Hver daglig dosis gives i én række og indeholder tre 20 mg kapsler: 
Each daily dose is given in one row and contains three 20 mg capsules:
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE BLISTERKORT, 100 mg dosis 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING BLISTER CARD, 100 mg dose
140 mg dosis 
140 mg Dose
Navn og adresse på den fremstiller, der er ansvarlig for batchfrigivelse Catalent UK Packaging Limited 
Name and address of the manufacturer responsible for batch release
Bivirkninger med osteonekrose af kæben (ONJ) er blevet observeret med cabozantinib. 
Events of osteonecrosis of the jaw (ONJ) have been observed with cabozantinib.
Reversibelt posterior leukoencephalopatisyndrom 
Reversible posterior leukoencephalopathy syndrome
Luftveje, thorax og mediastinum dysfoni, orofaryngeale smerter ikkegastrointestinal fistel (inklusive trakeal, pneumomediastin um, trakeoøsofageal), lungeemboli, blødning i luftvejene (inklusive pulmonær, bronchial, trakeal), aspirationspneum oni atelektase, faryngealt ødem, pneumonitis 
Respiratory, thoracic, and mediastinal disorders dysphonia, oropharyngeal pain non-gastrointestinal fistula (including tracheal, pneumomediastinu m, tracheooesophageal), pulmonary embolism, respiratory tract haemorrhage (including pulmonary, bronchial, tracheal), pneumonia aspiration atelectasis, pharyngeal oedema, pneumonitis
4 “Bivirkninger”. 
See also section 4 “Possible side effects”.
EU/1/13/890/002 7 x 20 mg og 7 x 80 mg kapsler (100 mg/dag dosis som forsyning til 7 dage) EU/1/13/890/003 21 x 20 mg og 7 x 80 mg kapsler (140 mg/dag dosis som forsyning til 7 dage) EU/1/13/890/005 56 kapsler (4 blisterkort med 7 x 20 mg og 7 x 80 mg) (100 mg/dag dosis som forsyning til 28 dage) 
EU/1/13/890/002 7 x 20 mg and 7 x 80 mg capsules (100 mg/day dose for a 7-day supply) EU/1/13/890/003 21 x 20 mg and 7 x 80 mg capsules (140 mg/day dose for a 7-day supply) EU/1/13/890/005 56 capsules (4 blister cards of 7 x 20 mg and 7 x 80 mg) (100 mg/day dose for 28 day supply)
• Kulderystelser, rysten 
• Chills, tremors
Ikke almindelige bivirkninger (kan påvirke 1 ud af 100 mennesker) 
Uncommon side effects (may affect 1 in 100 people)
• Inflammation i øjnene, grå stær 
• Inflammation in the eye, cataracts
COMETRIQ 20 mg kapsler er grå og har “XL184 20mg” trykt på den ene side. 
What COMETRIQ looks like and contents of the pack COMETRIQ 20 mg capsules are grey and have “XL184 20mg” printed on one side.
Graviditet, puerperium og den perinatale periode amenorré, vaginalblødning 
Reproductive system and breast disorders amenorrhoea, vaginal haemorrhage
Denne indlægsseddel blev senest ændret Dette lægemiddel er godkendt under ”betingede omstændigheder”. 
This medicinal product has been authorised under a so-called ‘conditional approval' scheme.
100 mg dosis 
100 mg Dose
60 mg dosis 
60 mg Dose
CYP3A4-inducere og -hæmmere 
CYP3A4 inducers and inhibitors
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE BLISTERKORT 140 mg dosis 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING BLISTER CARD 140 mg dose
• Abnorm forbindelse af vævet i dit luftrør, spiserør eller lunger 
• Abnormal connection of the tissue in your trachea (airway), oesophagus, or lungs
• Nedsat aktivitet i skjoldbruskkirtlen; symptomer kan omfatte: træhed, vægtøgning, 
• Reduced thyroid activity; symptoms can include: tiredness, weight gain, constipation, feeling cold and dry skin
Hver 140 mg daglig dosis består af en kombination af tre grå 20 mg kapsel og én orange 80 mg kapsel. 
Each 140 mg daily dose contains a combination of three grey 20 mg capsules and one orange 80 mg capsule.
Pakning til 100 mg daglig dosis 
Pack for the 100 mg daily dose
Sådan skal du tage COMETRIQ 
How to take COMETRIQ
Pakning til 140 mg daglig dosis 
Pack for the 140 mg daily dose
140 mg/dag dosis 
140 mg/day dose
Hypertension er blevet observeret med cabozantinib. 
Hypertension has been observed with cabozantinib.
Hver 60 mg daglig dosis består af tre grå 20 mg kapsler. 
Each 60 mg daily dose contains a combination of three grey 20 mg capsules.
Hver 100 mg daglig dosis består af én grå 20 mg kapsel og én orange 80 mg kapsel. 
Each 100 mg daily dose contains a combination of one grey 20 mg capsule and one orange 80 mg capsule.
Disse bivirkninger er ikke observeret i kliniske studier, men anses for at være klinisk relevante: 
Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:
EU/1/13/890/001 21 x 20 mg kapsler (60 mg/dag dosis som forsyning til 7 dage) EU/1/13/890/004 84 kapsler (4 blisterkort med 21 x 20 mg) (60 mg/dag dosis som forsyning til 
EU/1/13/890/001 21 x 20 mg capsules (60 mg/day dose for a 7-day supply) EU/1/13/890/004 84 capsules (4 blister cards of 21 x 20 mg) (60 mg/day dose for a 28 day supply)
21 x 20 mg kapsler (60 mg/dag dosis til forsyning i 7 dage) Hver 60 mg daglig dosis består af tre grå 20 mg kapsler. 
Pack for the 60 mg daily dose 21 x 20 mg capsules (60 mg/day dose for a 7-day supply) Each 60 mg daily dose contains three grey 20 mg capsules.
100 mg/dag dosis 
100 mg/day dose
COMETRIQ 80 mg kapslerne indeholder cabozantinib (S)-malat svarende til 80 mg cabozantinib. 
The COMETRIQ 80 mg capsules contain cabozantinib (S)-malate equivalent to 80 mg of cabozantinib.
• Inflammation af spiserøret; symptomer kan omfatte halsbrand, brystsmerter, følen sig syg, 
• Inflammation of the oesophagus; symptoms can include heartburn, chest pain, feeling sick, altered taste, bloating, belching and indigestion
Blisterkortet for 100 mg daglig dosis indeholder syv 80 mg kapsler og syv 20 mg kapsler som 7 daglige doser totalt. 
The 100 mg daily dose blister card contains seven 80 mg capsules and seven 20 mg capsules as 7 daily doses in total.
Hver daglig dosis findes i én række og indeholder én 80 mg kapsel og én 20 mg kapsel: 
Each daily dose is provided in one row and contains one 80 mg capsule and one 20 mg capsule:
Hver daglig dosis findes i én række og indeholder én 80 mg kapsel og tre 20 mg kapsler: 
Each daily dose is provided in one row and contains one 80 mg capsule and three 20 mg capsules:
60 mg/dag dosis 
60 mg/day dose
COMETRIQ 80 mg hårde kapsler 
COMETRIQ 80 mg hard capsules
• Tab af smagsans 
• Joint pain, muscle spasms
COMETRIQ 20 mg hårde kapsler 
COMETRIQ 20 mg hard capsules
Sårkomplikationer er blevet observeret med cabozantinib. 
Wound complications have been observed with cabozantinib.
Blisterkortet for 60 mg daglig dosis indeholder énogtyve 20 mg kapsler som 7 daglige doser totalt. 
The 60 mg daily dose blister card contains twenty-one 20 mg capsules as 7 daily doses in total.
Nyrer og urinveje proteinuri, dysuri, hæmaturi akut nyreinsufficiens 
Renal and urinary disorders proteinuria, dysuria, haematuria renal failure acute
7 x 20 mg og 7 x 80 mg kapsler (100 mg/dag dosis som forsyning til 7 dage) eller 21 x 20 mg og 7 x 80 mg kapsler (140 mg/dag dosis som forsyning til 7 dage) 
7 x 20 mg and 7 x 80 mg capsules (100 mg/day dose for a 7-day supply) 21 x 20 mg and 7 x 80 mg capsules (140 mg/day dose for a 7-day supply)